Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma

Overview of attention for article published in Cancer (0008543X), April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 38 X users

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 41 X posts from 38 X users, with an upper bound of 172,185 followers.

RT @Transplant_Doc: Bortezomib‐based (N=146) vs lenalidomide (N=357) maintenance in HRMM. More patients had ISS III and >/=2 HR cytogeneti…

@Phhersh @BijoyTelivala @ManniMD1 @VincentRK @RahulBanerjeeMD @Abdallah81MD @Drjhoffmanmiami @rajshekharucms @AaronGoodman33 @OncBrothers @Rfonsi1 @karmanoscancer Don’t think simply adding bortezomib (at least without other agents) likely to be the answer…

Dr Bumma is AWESOME! 😄😄😄

RT @OSUHematology: 📢Myeloma expert, Naresh Bumma, MD published “Impact of bortezomib-based versus lenalidomide maintenance therapy on outco…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 37 additional X posts.